Wockhardt spanked again by FDA as agency ticks off violations at new sterile injectables plant

Eric Palmer

saw a new that will make injectable drugs as its best shot at restoring a U.S. business devastated by FDA product bans. But the Indian company said today that facility–a plant it has called "one of a kind in Asia"–will not be shipping to the U.S. any time soon after the FDA found shortcomings during a recent inspection to judge whether it is fit for U.S. exports.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS